Related Experiment Video
Updated: Jul 6, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Progress of non-small-cell lung cancer with ROS1 rearrangement
Xin Yang1, Zhe Tang2, Jing Li1
1Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abstract:
ROS1 rearrangement is found in 0.9%-2.6% of people with non-small-cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) target ROS1 and can block tumor growth and provide clinical benefits to patients. This review summarizes the current knowledge on ROS1 rearrangements in NSCLCs, including the mechanisms of ROS1 oncogenicity, epidemiology of ROS1-positive tumors, methods for detecting rearrangements, molecular characteristics, therapeutic agents, and mechanisms of drug resistance.
Insights
ROS1 rearrangements occur in non-small-cell lung cancer (NSCLC) and can be targeted by tyrosine kinase inhibitors (TKIs). This review covers ROS1 oncogenicity, detection, and resistance mechanisms in NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- ROS1 rearrangements are identified in 0.9%-2.6% of non-small-cell lung cancer (NSCLC) cases.
- Tyrosine kinase inhibitors (TKIs) targeting ROS1 show efficacy in blocking tumor growth and improving patient outcomes.
Purpose of the Study:
- To provide a comprehensive review of current knowledge regarding ROS1 rearrangements in NSCLC.
- To elucidate the oncogenic mechanisms, epidemiology, detection, molecular features, therapies, and resistance patterns associated with ROS1-positive NSCLC.
Main Methods:
- Literature review of studies on ROS1 rearrangements in NSCLC.
- Synthesis of information on oncogenic pathways, diagnostic methods, and clinical data.
Main Results:
- ROS1 rearrangements drive oncogenesis through various mechanisms.
- Diverse methods exist for detecting ROS1 rearrangements, impacting treatment selection.
- Understanding molecular characteristics and resistance mechanisms is crucial for effective TKI therapy.
Conclusions:
- ROS1 rearrangements represent a significant actionable target in NSCLC.
- Targeted therapies like TKIs offer clinical benefits for patients with ROS1-positive NSCLC.
- Continued research into resistance mechanisms will refine future treatment strategies.
More Related Videos
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...